Search results
Your search for TFRC returned no results
Showing 651 to 700 of 2490 results for term
Showing 651 to 700 of 2490 results for term
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.
View recommendations for TA274Show all sections
seizure control and resolution of the hypsarrhythmic EEG influence the long-term developmental and cognitive outcomes more than the...
Transient loss of consciousness ('blackouts') in over 16s (CG109)
This guideline covers assessment, diagnosis and referral for people over 16 who have had a transient loss of consciousness (TLoC; also called a blackout). It aims to improve care for people with TLoC by specifying the most effective assessments and recommending when to refer to a specialist.
Recommendation ID DG18/4 Question What is the impact and longer-term clinical outcomes of adding procalcitonin testing to standard...
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
wellbeing over time? Which indicators and datasets can be used to assess the long-term benefits of interventions aimed at improving the...
This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.
Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)
Evidence-based recommendations on imatinib for people with chronic myeloid leukaemia.
Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
This quality standard covers activities undertaken by local authorities and general dental practices to improve oral health. It particularly focuses on people at high risk of poor oral health or who find it difficult to use dental services. It describes high-quality care in priority areas for improvement.
View quality statements for QS139Show all sections
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.
This quality standard covers preventing further cardiovascular disease after a myocardial infarction (heart attack). It includes assessment and cardiac rehabilitation. It describes high-quality care in priority areas for improvement.
View quality statements for QS99Show all sections
Sections for QS99
- Quality statements
- Quality statement 1: Assessment of left ventricular function
- Quality statement 2: Referral for cardiac rehabilitation
- Quality statement 3: Communication with primary care
- Quality statement 4: Cardiac rehabilitation – assessment appointment
- Quality statement 5 (developmental): Options for cardiac rehabilitation
- Update information
- About this quality standard
Community engagement: improving health and wellbeing (QS148)
This quality standard covers community engagement approaches to improve health and wellbeing and reduce health inequalities, and initiatives to change behaviours that harm people’s health. This includes building on the strengths and capabilities of communities, helping them to identify their needs and working with them to design and deliver initiatives and improve equity.
This indicator covers admission rates due to diabetic ketoacidosis in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG64
Evidence-based recommendations on risdiplam (Evrysdi) for 5q spinal muscular atrophy (SMA) in people of all ages.
selection, report on functional improvement and quality of life, and provide long-term follow-up data. Any explanatory notes(if...
endovascular aneurysm repair. All complications should be reported. Long-term outcomes should be described as data become available....
myAIRVO2 for the treatment of chronic obstructive pulmonary disease (MIB161)
NICE has developed a medtech innovation briefing (MIB) on myAIRVO2 for the treatment of chronic obstructive pulmonary disease .
symptom scores, quality of life and the need for retreatment in the long term. All complications should be reported. NICE may update...
This indicator covers the proportion of people treated by Improving Access to Psychological Therapies (IAPT) for anxiety disorders who return to full function. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG54
Diabetes: admission rates (renal replacement therapy) (IND45)
This indicator covers admission rates for renal replacement therapy in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG63
This indicator covers producing a register of all patients aged 16 years and over with rheumatoid arthritis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM55
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)
Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by narcolepsy in adults.
Violence and aggression: short-term management in mental health, health and community settings
Discontinued Reference number: GID-NG10397
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)
Evidence-based recommendations on ibrutinib (Imbruvica) with venetoclax (Venclyxto) for untreated chronic lymphocytic leukaemia in adults.
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)
Evidence-based recommendations on berotralstat (Orladeyo) for preventing recurrent attacks of hereditary angioedema in people 12 years and older.
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.
Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)
Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.
What key factors ensure people continue to walk or cycle in the long term (over a year)? How do individual interventions (such as...
This quality standard covers diagnosing and managing hypertension (high blood pressure) and pre-eclampsia during pregnancy, labour and birth. It also covers advice for women with hypertension who may become pregnant and postnatal care for women who have had hypertension or pre-eclampsia. It describes high-quality care in priority areas for improvement.
View quality statements for QS35Show all sections
Sections for QS35
- Quality statements
- Quality statement 1: Pre-pregnancy advice for women with treated hypertension
- Quality statement 2: Antenatal assessment of pre-eclampsia risk
- Quality statement 3: Antenatal blood pressure targets
- Quality statement 4: Assessing women with severe hypertension in pregnancy
- Quality statement 5: Admission to hospital for women with pre-eclampsia
- Quality statement 6: Timing of birth for women with pre-eclampsia
- Quality statement 7: Transfer of information about ongoing management
This indicator covers the percentage of male patients with diabetes with a record of being asked about erectile dysfunction in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM51
This indicator covers admission rates due to stroke in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG62
safety has shown an increased risk of serious complications in the longer term. This includes an increased risk of myocardial infarction...
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)
Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults.
including urgency. Clinical outcomes should be measured in the short and long term. Any explanatory notes(if applicable) Source guidance...
This indicator covers admission rates for people with diabetes due to complications associated with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG58
This quality standard covers care and support for adults with cerebral palsy (aged 25 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS191Show all sections
Telbivudine for the treatment of chronic hepatitis B (TA154)
Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.
Weight management: advice for people living with overweight (18 to 39 years) (IND319)
This indicator covers the percentage of patients aged 18 to 39 years with a BMI of 23 kg/m2 to 27.4 kg/m2 (or 25 kg/m2 to 29.9 kg/m2 if ethnicity is recorded as White) in the preceding 12 months who have been given weight management advice within 90 days of the BMI being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the percentage of patients with a new diagnosis of CKD stage G3a-G5 (on the register, within the preceding 12 months) who had eGFR and ACR (urine albumin to creatinine ratio) measurements recorded within 90 days before or after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM216
Pregnancy and neonates: planned caesarean after 39 weeks (IND24)
This indicator covers the proportion of pregnant women having a planned caesarean section who have the procedure carried out at or after 39 weeks 0 days. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG37
This indicator covers mortality rates directly associated with VTE. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG80
intravascular ultrasound. Research outcomes should include data on medium- and long-term clinical outcomes, including the need for...
This indicator covers the proportion of births resulting in a neonatal unit admission. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG36
Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.
This guideline covers promoting physical activity for children and young people aged under 18 at home, preschool, school and in the community. It includes raising awareness of the benefits of physical activity, listening to what children and young people want, planning and providing spaces and facilities, and helping families build physical activity into their daily lives.
Care and support of people growing older with learning disabilities (NG96)
This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.
This indicator covers admission rates due to angina in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG59
This indicator covers the percentage of patients with diabetes who have a record of a dietary review by a suitably competent professional in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM28